Global Blood Therapeutics

New sickle cell drugs priced too high, ICER says
New sickle cell drugs priced too high, ICER says
BioPharma Dive
sickle cell disease
drug pricing
ICER
Novartis
Global Blood Therapeutics
RWE
Adakveo
Oxbryta
Flag link:
GBT takes a page from HIV playbook as it embarks on Oxbryta launch
GBT takes a page from HIV playbook as it embarks on Oxbryta launch
Fierce Pharma
Global Blood Therapeutics
drug launches
Oxbryta
sickle cell disease
HIV
Flag link:
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Endpoints
ICER
sickle cell disease
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
Emmaus Life Sciences
Endari
Flag link:
5 biopharmas to watch as the decade's last earnings kick off
5 biopharmas to watch as the decade's last earnings kick off
BioPharma Dive
earnings
Novartis
Biogen
Eli Lilly
Global Blood Therapeutics
Bluebird Bio
Flag link:
3 Rare Disease Drug Launches to Watch in 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
Flag link:
5 New Drug Approvals the FDA Gave Top Priority
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
Flag link:
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Flag link:
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule
Xconomy
Global Blood Therapeutics
FDA
sickle cell disease
voxelotor
Oxbryta
Flag link:
Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell
Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell
Motley Fool
Global Blood Therapeutics
voxelotor
Novartis
Adakveo
sickle cell disease
Flag link:
2 Biotechs With Approaching Drug Approvals
2 Biotechs With Approaching Drug Approvals
Motley Fool
drug approvals
drug launches
FDA
voxelotor
Global Blood Therapeutics
Immunomedics
sacituzumab govitecan
Flag link:
Why Global Blood Therapeutics Stock Jumped 10.9% Today
Why Global Blood Therapeutics Stock Jumped 10.9% Today
Motley Fool
Global Blood Therapeutics
FDA
voxelotor
sickle cell disease
Flag link:
GBT sickle cell trial hits endpoint ahead of NDA filing
GBT sickle cell trial hits endpoint ahead of NDA filing
Fierce Biotech
Global Blood Therapeutics
sickle cell disease
FDA
voxelotor
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
[audio+transcript] 6 Biotech Stocks to Watch Now
[audio+transcript] 6 Biotech Stocks to Watch Now
Motley Fool
Biogen
Bluebird Bio
Global Blood Therapeutics
Aimmune Therapeutics
Vertex Pharmaceuticals
Sarepta Therapeutics
Flag link:
Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval
Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval
EP Vantage
Vertex Pharma
cystic fibrosis
Symdeko
Kalydeco
Global Blood Therapeutics
voxelotor
sickle cell disease
Flag link:
Once lauded for its clinical success, Roche casts off cardio program inclacumab for a mere $2M to Global Blood Therapeutics
Once lauded for its clinical success, Roche casts off cardio program inclacumab for a mere $2M to Global Blood Therapeutics
Endpoints
Roche
inclacumab
Global Blood Therapeutics
Flag link:
GBT touts positive sickle cell trial, but shares yo-yo as investors mull data
GBT touts positive sickle cell trial, but shares yo-yo as investors mull data
Fierce Biotech
Global Blood Therapeutics
sickle cell disease
voxelotor
clinical trials
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:
Novo Nordisk in Talks to Buy Global Blood Therapeutics
Novo Nordisk in Talks to Buy Global Blood Therapeutics
Investopedia
Novo Nordisk
M&A
Global Blood Therapeutics
Flag link:
Shares in Global Blood climb after positive study results for experimental sickle cell treatment
Shares in Global Blood climb after positive study results for experimental sickle cell treatment
First Word Pharma
Global Blood Therapeutics
GBT440
sickle cell disease
Flag link:

Pages